BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29063804)

  • 41. Outcome and surgical strategy in critical sites in cases of psuedomyxoma peritonei.
    Mahmoud AM; Hussein MM; Moneer MM
    J Egypt Natl Canc Inst; 2016 Dec; 28(4):249-255. PubMed ID: 27658904
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei.
    Benhaim L; Faron M; Gelli M; Sourrouille I; Honoré C; Delhorme JB; Elias D; Goere D
    Surg Oncol; 2019 Jun; 29():78-83. PubMed ID: 31196498
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in 632 patients with pseudomyxoma peritonei of appendiceal origin: A single institution experience.
    Fung X; Li IC; Chandrakumaran K; Cecil T; Dayal S; Tzivanakis A; Moran B; Mohamed F
    Eur J Surg Oncol; 2022 Jul; 48(7):1614-1618. PubMed ID: 35168851
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
    Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
    In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis.
    Marcotte E; Dubé P; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Sideris L
    World J Surg Oncol; 2014 Nov; 12():332. PubMed ID: 25380618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preoperative systemic chemotherapy does not benefit for appendiceal pseudomyxoma peritonei.
    Ma R; Lu D; Xue S; Fan X; Zhai X; Wang C; Xu H; Pang S
    ANZ J Surg; 2023 Jan; 93(1-2):219-226. PubMed ID: 36136728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic metastases from low-grade and high-grade pseudomyxoma peritonei: Treatments and outcomes.
    Baratti D; Milito P; Kusamura S; Martin Roman L; Guaglio M; Deraco M
    Eur J Surg Oncol; 2022 Jul; 48(7):1590-1597. PubMed ID: 35090796
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience.
    Narasimhan V; Wilson K; Britto M; Warrier S; Lynch AC; Michael M; Tie J; Akhurst T; Mitchell C; Ramsay R; Heriot A
    J Gastrointest Surg; 2020 Apr; 24(4):899-906. PubMed ID: 31090036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study.
    Trecourt A; Bakrin N; Glehen O; Gertych W; Villeneuve L; Isaac S; Benzerdjeb N; Fontaine J; Genestie C; Dartigues P; Leroux A; Quenet F; Marchal F; Odin C; Khellaf L; Svrcek M; Thierry S; Augros M; Omar A; Devouassoux-Shisheboran M; Kepenekian V;
    Ann Surg Oncol; 2024 May; 31(5):3325-3338. PubMed ID: 38341381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A case of pseudomyxoma peritonei arising from a perforated intraductal papillary mucinous neoplasm that underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Yoshizaki Y; Gohda Y; Inagaki F; Kataoka A; Takemura N; Miyazaki H; Igari T; Kiyomatsu T; Yano H; Kokudo N
    Clin J Gastroenterol; 2024 Feb; 17(1):188-197. PubMed ID: 37980306
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?
    López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P
    Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of definitive stoma after surgery for peritoneal malignancy in 958 patients: comparative study between complete cytoreductive surgery and maximal tumor debulking.
    Riss S; Chandrakumaran K; Dayal S; Cecil TD; Mohamed F; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):392-5. PubMed ID: 25238953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis.
    Chua TC; Liauw W; Zhao J; Morris DL
    Int J Clin Oncol; 2013 Jun; 18(3):439-46. PubMed ID: 22415741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anaesthetic management of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective audit.
    Shiralkar SP; Kerr P; Scott J; Sivalingam P
    Anaesth Intensive Care; 2017 Jul; 45(4):490-498. PubMed ID: 28673220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma.
    Mercier F; Jeremie G; Alyami M; Delphine V; Vahan K; Pascal R; Sylvie I; Guillaume P; Olivier G
    Surg Endosc; 2020 Nov; 34(11):4916-4923. PubMed ID: 31792692
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Managing Recurrent Pseudomyxoma Peritonei in 430 Patients After Complete Cytoreduction and HIPEC: A Dilemma for Patients and Surgeons.
    Ahmadi N; Kostadinov D; Sakata S; Ball WR; Gandhi J; Carr NJ; Tzivanakis A; Dayal SP; Mohamed F; Cecil TD; Moran BJ
    Ann Surg Oncol; 2021 Nov; 28(12):7809-7820. PubMed ID: 34041626
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Randle RW; Griffith KF; Fino NF; Swett KR; Stewart JH; Shen P; Levine EA; Votanopoulos KI
    J Surg Res; 2015 Jun; 196(2):229-34. PubMed ID: 25881787
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy.
    Chua TC; Chong CH; Liauw W; Zhao J; Morris DL
    Ann Surg; 2012 Aug; 256(2):342-9. PubMed ID: 22750758
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preoperative carcinoembryonic antigen level predicts prognosis in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Canbay E; Ishibashi H; Sako S; Mizumoto A; Hirano M; Ichinose M; Takao N; Yonemura Y
    World J Surg; 2013 Jun; 37(6):1271-6. PubMed ID: 23467926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei in a liver-transplanted patient: a case report.
    Thorgersen EB; Melum E; Folseraas T; Larsen SG; Line PD
    World J Surg Oncol; 2018 Sep; 16(1):180. PubMed ID: 30185175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.